Medication Management in Critically Ill Patients

Introduction to Medication Management

• Medication management in critically ill patients requires careful consideration of cardiovascular safety and efficacy, as well as treatment guidelines, according to the European Heart Journal and Critical Care Medicine guidelines 1, 2

Cardiovascular Safety and Efficacy

• Quetiapine is recommended for patients with heart failure due to its benzodiazepine-like hemodynamic effects and less concern for reduction in cardiac output compared to other sedatives, as recommended by the European Heart Journal 1
• Quetiapine has been shown to reduce the duration of delirium in ICU patients, according to the Critical Care Medicine guidelines 2

Treatment Guidelines

• No double-blind, randomized, placebo-controlled trials have definitively established the efficacy or safety of any antipsychotic agent for delirium in ICU patients, according to the Critical Care Medicine guidelines 2
• The FDA has issued a black box warning for montelukast, highlighting the significant risk of neuropsychiatric events, including suicidal thoughts and behaviors, and noting that the benefits may not outweigh the risks, especially for mild symptoms, according to the FDA guidelines 3
• Patients on antipsychotics and antidepressants require close monitoring for suicidal ideation, especially during the first 1-2 months of treatment, with regular assessment of therapeutic response and adverse effects beginning within this timeframe, as recommended by the American College of Physicians and the American Academy of Child and Adolescent Psychiatry 4, 5

Medication Dosing and Administration

• The recommended initial dose of Vraylar is 1.5 mg daily, with slow titration to the effective dose (1.5-6 mg for schizophrenia; 1.5-3 mg for bipolar depression or MDD), avoiding rapid dose escalation which may increase side effect risk, as recommended by the American Academy of Child and Adolescent Psychiatry 5
• Aripiprazole 5mg daily is less likely to cause extrapyramidal symptoms (EPS), but caution is advised when switching from strong dopamine antagonists like paliperidone, as this can potentially worsen psychosis, according to the American Psychiatric Association 6
• Risperidone can be titrated up to 2mg daily in divided doses if needed, and is available as an orally disintegrating tablet for better adherence, as recommended by the American Academy of Family Physicians 7
• Alternative options include quetiapine 25mg twice daily for additional sedation and anxiolytic effects, with gradual titration especially in elderly or those with hepatic impairment, as recommended by the American Academy of Family Physicians 8
• Lorazepam 0.5-1mg PRN (maximum 2mg) can be added for acute management of severe agitation or imminent suicide risk, with caution to avoid combining benzodiazepines with olanzapine due to risk of respiratory depression, as recommended by the American Academy of Family Physicians 8

Monitoring and Adjustments

• During any medication switch, monitor closely for worsening of suicidal thoughts, emergence of withdrawal symptoms, changes in mood or behavior, and sleep disturbances, as recommended by the National Institute of Mental Health 6
• Monitor for improvement in hallucinations and suicidal ideation daily for the first week, and assess for extrapyramidal symptoms (EPS) as risperidone has an increased risk of EPS at doses >6mg/day, as recommended by the American Academy of Family Physicians 8
• Consider inpatient admission if suicidal ideation persists or worsens despite medication adjustment, as recommended by the American Academy of Family Physicians 8

Non-Pharmacological Interventions

• Non-pharmacological interventions, such as reorientation strategies, sleep optimization, cognitive stimulation, and regular assessment of suicide risk, should be implemented alongside medication adjustments, as recommended by the National Comprehensive Cancer Network and the American College of Oncology 9, 8, 2
• Multicomponent non-pharmacological interventions, including reorientation strategies, cognitive stimulation, sleep optimization, early mobilization and rehabilitation, and ensuring use of hearing aids and eyeglasses, should be implemented concurrently with pharmacological treatment, as recommended by the National Comprehensive Cancer Network and the American College of Oncology 9, 8, 2

Special Considerations

• Elderly patients require dose reduction for both medications to minimize fall risk, which is significantly increased with the combination, as recommended by the American Academy of Family Physicians 10
• Patients with severe pulmonary insufficiency face heightened risks when given this combination, necessitating careful assessment and monitoring, as recommended by the American Academy of Family Physicians 8
• Patients with hepatic impairment require dose adjustments for both medications to prevent adverse effects, as recommended by the American Academy of Family Physicians 8

Common Pitfalls and Safety Considerations

• Common pitfalls to avoid when managing antipsychotic medication include switching too quickly between antipsychotics without proper cross-titration, failing to reduce doses appropriately in elderly or medically compromised patients, and not monitoring for metabolic effects, and using excessive doses in elderly patients, as recommended by the American Academy of Family Physicians and the National Institute of Mental Health 8, 2
• Quetiapine is a first-line non-benzodiazepine option for anxiety management, with a dose of 25 mg PRN, and is particularly useful for anxiety with delirium, but should be used with caution in patients with baseline QT prolongation, as recommended by the American Academy of Family Physicians and the National Institute of Mental Health 11, 8, 2
• Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) are recommended as first-line pharmacotherapy for long-term anxiety management, along with cognitive behavioral therapy, and should be used in conjunction with non-pharmacological interventions to optimize treatment outcomes, as recommended by the American Academy of Family Physicians and the National Institute of Mental Health 11
• Benzodiazepines should be monitored for excessive sedation and respiratory depression, and have an increased risk of falls, particularly in elderly patients, with a risk of dependence with prolonged use, as recommended by the American Academy of Family Physicians and the National Institute of Mental Health 11, 8